Islet β cell failure in type 2 diabetes

Journal of Clinical Investigation

Volumn 116, Issue 7, 2006, Pages 1802-1812

  Prentki, Marc ^a   Nolan, Christopher J ^b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^c CANBERRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MALONYL COENZYME A;

CELL DAMAGE; CELL FUNCTION; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GLYCATION; GLYCOSYLATION; HUMAN; INSULIN RESISTANCE; LIPOLYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRENATAL DEVELOPMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS;

EID: 33745863033     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29103     Document Type: Review

References (125)

1. Zimmet, P., Alberti, K.G., and Shaw, J. 2001. Global and societal implications of the diabetes epidemic. Nature. 414:782-787.
2. Martin, B.C., et al. 1992. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 340:925-929.
3. Porte, D. 2001. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab. Res. Rev. 17:181-188.
4. Prentki, M., Joly, E., El-Assaad, W., and Roduit, R. 2002. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes. 51(Suppl. 3):S405-S413.
5. Leahy, J.L. 2005. Pathogenesis of type 2 diabetes mellitus. Arch. Med. Res. 36:197-209.
6. Poitout, V., and Robertson, R.P. 2002. Minireview: secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology. 143:339-342.
7. Weyer, C., Bogardus, C., Mott, D.M., and Pratley, R.E. 1999. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 104:787-794.
8. Butler, A.E., et al. 2003. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 52:102-110.
9. Godsland, I.F., Jeffs, J.A., and Johnston, D.G. 2004. Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia. 47:1157-1166.
10. Steil, G.M., et al. 2001. Adaptation of beta-cell mass to substrate oversupply: enhanced function with normal gene expression. Am. J. Physiol. Endocrinol. Metab. 280:E788-E796.
11. Jetton, T.L., et al. 2005. Mechanisms of compensatory beta-cell growth in insulin-resistant rats: roles of Akt kinase. Diabetes. 54:2294-2304.
12. Liu, Y.Q., Jetton, T.L., and Leahy, J.L. 2002. Betacell adaptation to insulin resistance. Increased pyruvate carboxylase and malate-pyruvate shuttle activity in islets of nondiabetic Zucker fatty rats. J. Biol. Chem. 277:39163-39168.
13. Chen, C., Hosokawa, H., Bumbalo, L.M., and Leahy, J.L. 1994. Mechanism of compensatory hyperinsulinemia in normoglycemic insulin-resistant spontaneously hypertensive rats. Augmented enzymatic activity of glucokinase in b-cells. J. Clin. Invest. 94:399-404.
14. Srinivasan, S., Bernal-Mizrachi, E., Ohsugi, M., and Permutt, M.A. 2002. Glucose promotes pancreatic islet beta-cell survival through a PI 3-kinase/Akt-signaling pathway. Am. J. Physiol. Endocrinol. Metab. 283:E784-E793.
15. Van Citters, G.W., et al. 2002. Elevated glucagon-like peptide-1-(7-36)-amide, but not glucose, associated with hyperinsulinemic compensation for fat feeding. J. Clin. Endocrinol. Metab. 87:5191-5198.
16. Drucker, D.J. 2006. The biology of incretin hormones. Cell Metab. 3:153-165.
17. Van Haeften, T.W., and Twickler, T.B. 2004. Insulin-like growth factors and pancreas beta cells. Eur. J. Clin. Invest. 34:249-255.
18. Okamoto, H., et al. 2006. Role of the forkhead protein FoxO1 in β cell compensation to insulin resistance. J. Clin. Invest. 116:775-782. doi:10.1172/JCI24967.
19. Jhala, U.S., et al. 2003. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev. 17:1575-1580.
20. Buteau, J., Foisy, S., Joly, E., and Prentki, M. 2003. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 52:124-132.
21. Itoh, Y., et al. 2003. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 422:173-176.
22. Hardy, S., St-Onge, G.G., Joly, E., Langelier, Y., and Prentki, M. 2005. Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40. J. Biol. Chem. 280:13285-13291.
23. Prentki, M. 1996. New insights into pancreatic beta-cell metabolic signaling in insulin secretion. Eur. J. Endocrinol. 134:272-286.
24. Meglasson, M.D., and Matschinsky, F.M. 1986. Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabetes Metab. Rev. 2:163-214.
25. MacDonald, M.J. 1995. Feasibility of a mitochondrial pyruvate malate shuttle in pancreatic islets. Further implication of cytosolic NADPH in insulin secretion. J. Biol. Chem. 270:20051-20058.
26. Cline, G.W., Lepine, R.L., Papas, K.K., Kibbey, R.G., and Shulman, G.I. 2004. 13C NMR isotopomer analysis of anaplerotic pathways in INS-1 cells. J. Biol. Chem. 279:44370-44375.
27. Farfari, S., Schulz, V., Corkey, B., and Prentki, M. 2000. Glucose-regulated anaplerosis and cataplerosis in pancreatic beta-cells: possible implication of a pyruvate/citrate shuttle in insulin secretion. Diabetes. 49:718-726.
28. Maechler, P., and Wollheim, C.B. 1999. Mitochondrial glutamate acts as a messenger in glucoseinduced insulin exocytosis. Nature. 402:685-689.
29. Roduit, R., et al. 2004. A role for the malonyl-CoA/long-chain acyl-CoA pathway of lipid signaling in the regulation of insulin secretion in response to both fuel and nonfuel stimuli. Diabetes. 53:1007-1019.
30. Prentki, M., and Corkey, B.E. 1996. Are the beta-cell signaling molecules malonyl-CoA and cystolic longchain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes. 45:273-283.
31. Chen, C., Bumbalo, L., and Leahy, J.L. 1994. Increased catalytic activity of glucokinase in isolated islets from hyperinsulinemic rats. Diabetes. 43:684-689.
32. Lebrun, P., Montminy, M.R., and Van Obberghen, E. 2005. Regulation of the pancreatic duodenal homeobox-1 protein by DNA-dependent protein kinase. J. Biol. Chem. 280:38203-38210.
33. Dobbins, R.L., et al. 1998. A fatty acid- dependent step is critically important for both glucose- and non-glucose-stimulated insulin secretion. J. Clin. Invest. 101:2370-2376.
34. Steneberg, P., Rubins, N., Bartoov-Shifman, R., Walker, M.D., and Edlund, H. 2005. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 1:245-258.
35. Nolan, C.J., et al. 2006. Beta-cell compensation for insulin resistance in Zucker fatty rats: increased lipolysis and fatty acid signalling. Diabetologia. In press.
36. Ahren, B. 2000. Autonomic regulation of islet hormone secretion - implications for health and disease. Diabetologia. 43:393-410.
37. Kiba, T., et al. 1996. Ventromedial hypothalamic lesion-induced vagal hyperactivity stimulates rat pancreatic cell proliferation. Gastroenterology. 110:885-893.
38. Ahren, B., et al. 1997. Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism. 46:97-106.
39. Del Rio, G., et al. 1997. Cholinergic enhancement by pyridostigmine increases the insulin response to glucose load in obese patients but not in normal subjects. Int. J. Obes. Relat. Metab. Disord. 21:1111-1114.
40. Magnan, C., et al. 1999. Lipid infusion lowers sympathetic nervous activity and leads to increased β-cell responsiveness to glucose. J. Clin. Invest. 103:413-419.
41. Melloul, D., Marshak, S., and Cerasi, E. 2002. Regulation of insulin gene transcription. Diabetologia. 45:309-326.
42. Zhao, L., et al. 2005. The islet beta cell-enriched MafA activator is a key regulator of insulin gene transcription. J. Biol. Chem. 280:11887-11894.
43. Wicksteed, B., Alarcon, C., Briaud, I., Lingohr, M.K., and Rhodes, C.J. 2003. Glucose-induced translational control of proinsulin biosynthesis is proportional to preproinsulin mRNA levels in islet beta-cells but not regulated via a positive feedback of secreted insulin. J. Biol. Chem. 278:42080-42090.
44. Minn, A.H., et al. 2005. Increased insulin translation from an insulin splice-variant overexpressed in diabetes, obesity, and insulin resistance. Mol. Endocrinol. 19:794-803.
45. Lee, Y., et al. 1994. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc. Natl. Acad. Sci. U. S. A. 91:10878-10882.
46. Harmon, J.S., Gleason, C.E., Tanaka, Y., Poitout, V., and Robertson, R.P. 2001. Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes. 50:2481-2486.
47. Unger, R.H., and Zhou, Y.T. 2001. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes. 50(Suppl. 1):S118-S121.
48. Lee, Y., et al. 1997. Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes. 46:408-413.
49. Griffen, S.C., Wang, J., and German, M.S. 2001. A genetic defect in beta-cell gene expression segregates independently from the fa locus in the ZDF rat. Diabetes. 50:63-68.
50. Ruderman, N., and Prentki, M. 2004. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat. Rev. Drug Discov. 3:340-351.
51. Yu, X., et al. 2004. Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia. 47:2012-2021.
52. Federici, M., et al. 2001. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes. 50:1290-1301.
53. Maedler, K., et al. 2001. Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes. 50:1683-1690.
54. Kaiser, N., et al. 2005. Psammomys obesus, a model for environment-gene interactions in type 2 diabetes. Diabetes. 54(Suppl. 2):S137-S144.
55. Donath, M.Y., et al. 2005. Mechanisms of beta-cell death in type 2 diabetes. Diabetes. 54(Suppl. 2): S108-S113.
56. Andrikopoulos, S., et al. 2005. Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat diet. J. Endocrinol. 187:45-53.
57. Funkat, A., Massa, C.M., Jovanovska, V., Proietto, J., and Andrikopoulos, S. 2004. Metabolic adaptations of three inbred strains of mice (C57BL/6, DBA/2, and 129T2) in response to a high-fat diet. J. Nutr. 134:3264-3269.
58. Hummel, K.P., Coleman, D.L., and Lane, P.W. 1972. The influence of genetic background on expression of mutations at the diabetes locus in the mouse. I. C57BL-KsJ and C57BL-6J strains. Biochem. Genet. 7:1-13.
59. Kooptiwut, S., et al. 2002. Comparison of insulin secretory function in two mouse models with different susceptibility to beta-cell failure. Endocrinology. 143:2085-2092.
60. Giuffrida, F.M., and Reis, A.F. 2005. Genetic and clinical characteristics of maturity-onset diabetes of the young. Diabetes Obes. Metab. 7:318-326.
61. Parikh, H., and Groop, L. 2004. Candidate genes for type 2 diabetes. Rev. Endocr. Metab. Disord. 5:151-176.
62. Deeb, S.S., et al. 1998. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20:284-287.
63. Ek, J., et al. 2001. Mutation analysis of peroxisome proliferator- activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus. Diabetologia. 44:2220-2226.
64. Neve, B., et al. 2005. Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function. Proc. Natl. Acad. Sci. U. S. A. 102:4807-4812.
65. Grant, S.F., et al. 2006. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 38:320-323.
66. Weedon, M.N., et al. 2003. Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. Am. J. Hum. Genet. 73:1208-1212.
67. Gloyn, A.L., et al. 2003. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 52:568-572.
68. Ong, K.K., et al. 1999. The insulin gene VNTR, type 2 diabetes and birth weight. Nat. Genet. 21:262-263.
69. Gunton, J.E., et al. 2005. Loss of ARNT/HIF1beta mediates altered gene expression and pancreaticislet dysfunction in human type 2 diabetes. Cell. 122:337-349.
70. Mootha, V.K., et al. 2003. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34:267-273.
71. Lowell, B.B., and Shulman, G.I. 2005. Mitochondrial dysfunction and type 2 diabetes. Science. 307:384-387.
72. Simmons, R.A., Suponitsky-Kroyter, I., and Selak, M.A. 2005. Progressive accumulation of mitochondrial DNA mutations and decline in mitochondrial function lead to beta-cell failure. J. Biol. Chem. 280:28785-28791.
73. Barker, D.J., et al. 1993. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 36:62-67.
74. Pettitt, D.J., and Knowler, W.C. 1998. Long-term effects of the intrauterine environment, birth weight, and breast-feeding in Pima Indians. Diabetes Care. 21(Suppl. 2):B138-B141.
75. Jimenez-Chillaron, J.C., et al. 2005. Beta-cell secretory dysfunction in the pathogenesis of low birth weight-associated diabetes: a murine model. Diabetes. 54:702-711.
76. Aerts, L., and Van Assche, F.A. 2003. Intra-uterine transmission of disease. Placenta. 24:905-911.
77. Deng, S., et al. 2004. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes. 53:624-632.
78. Yoon, K.H., et al. 2003. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J. Clin. Endocrinol. Metab. 88:2300-2308.
79. Du, X., et al. 2003. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest. 112:1049-1057. doi:10.1172/JCI200318127.
80. Brownlee, M. 2003. A radical explanation for glucose-induced β cell dysfunction. J. Clin. Invest. 112:1788-1790. doi:10.1172/JCI200320501.
81. Krauss, S., et al. 2003. Superoxide-mediated activation of uncoupling protein 2 causes pancreatic β cell dysfunction. J. Clin. Invest. 112:1831-1842. doi:10.1172/JCI200319774.
82. Lameloise, N., Muzzin, P., Prentki, M., and Assimacopoulos-Jeannet, F. 2001. Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes. 50:803-809.
83. Armstrong, J.S., Whiteman, M., Yang, H., and Jones, D.P. 2004. The redox regulation of intermediary metabolism by a superoxide-aconitase rheostat. Bioessays. 26:894-900.
84. Robertson, R.P. 2004. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J. Biol. Chem. 279:42351-42354.
85. Martens, G.A., et al. 2005. Glucose suppresses superoxide generation in metabolically responsive pancreatic beta cells. J. Biol. Chem. 280:20389-20396.
86. Maestre, I., et al. 2003. Mitochondrial dysfunction is involved in apoptosis induced by serum withdrawal and fatty acids in the beta-cell line INS-1. Endocrinology. 144:335-345.
87. Iizuka, K., et al. 2002. Metabolic consequence of long-term exposure of pancreatic beta cells to free fatty acid with special reference to glucose insensitivity. Biochim. Biophys. Acta. 1586:23-31.
88. Boucher, A., et al. 2004. Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion and reversal with a malate analogue. J. Biol. Chem. 279:27263-27271.
89. Liu, Y.Q., Tornheim, K., and Leahy, J.L. 1999. Glucose-fatty acid cycle to inhibit glucose utilization and oxidation is not operative in fatty acid-cultured islets. Diabetes. 48:1747-1753.
90. MacDonald, M.J., Tang, J., and Polonsky, K.S. 1996. Low mitochondrial glycerol phosphate dehydrogenase and pyruvate carboxylase in pancreatic islets of Zucker diabetic fatty rats. Diabetes. 45:1626-1630.
91. MacDonald, M.J., Efendic, S., and Ostenson, C.G. 1996. Normalization by insulin treatment of low mitochondrial glycerol phosphate dehydrogenase and pyruvate carboxylase in pancreatic islets of the GK rat. Diabetes. 45:886-890.
92. Coleman, R.A., Lewin, T.M., Van Horn, C.G., and Gonzalez-Baro, M.R. 2002. Do long-chain acyl-CoA synthetases regulate fatty acid entry into synthetic versus degradative pathways? J. Nutr. 132:2123-2126.
93. Mulder, H., Yang, S., Winzell, M.S., Holm, C., and Ahren, B. 2004. Inhibition of lipase activity and lipolysis in rat islets reduces insulin secretion. Diabetes. 53:122-128.
94. Winzell, M.S., Svensson, H., Arner, P., Ahren, B., and Holm, C. 2001. The expression of hormone-sensitive lipase in clonal beta-cells and rat islets is induced by long-term exposure to high glucose. Diabetes. 50:2225-2230.
95. Peyot, M.L., et al. 2004. Hormone-sensitive lipase has a role in lipid signaling for insulin secretion but is nonessential for the incretin action of glucagon-like peptide 1. Diabetes. 53:1733-1742.
96. Cnop, M., Hannaert, J.C., Hoorens, A., Eizirik, D.L., and Pipeleers, D.G. 2001. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes. 50:1771-1777.
97. Busch, A.K., et al. 2005. Increased fatty acid desaturation and enhanced expression of stearoyl coenzyme A desaturase protects pancreatic beta-cells from lipoapoptosis. Diabetes. 54:2917-2924.
98. Maedler, K., Oberholzer, J., Bucher, P., Spinas, G.A., and Donath, M.Y. 2003. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes. 52:726-733.
99. Larter, C.Z., and Farrell, G.C. 2006. Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat? J. Hepatol. 44:253-261.
100. Tomas, E., et al. 2002. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl. Acad. Sci. U. S. A. 99:16309-16313.
101. Minokoshi, Y., et al. 2002. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 415:339-343.
102. Fryer, L.G., Parbu-Patel, A., and Carling, D. 2002. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277:25226-25232.
103. El-Assaad, W., et al. 2003. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology. 144:4154-4163.
104. Stefan, N., Stumvoll, M., Bogardus, C., and Tataranni, P.A. 2003. Elevated plasma nonesterified fatty acids are associated with deterioration of acute insulin response in IGT but not NGT. Am. J. Physiol. Endocrinol. Metab. 284:E1156-E1161.
105. Leiter, L.A., et al. 2005. Postprandial glucose regulation: new data and new implications. Clin. Ther. 27(Suppl. B):S42-S56.
106. Chiasson, J.L., et al. 2002. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 359:2072-2077.
107. Hardy, S., et al. 2003. Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells. A role for cardiolipin. J. Biol. Chem. 278:31861-31870.
108. Lupi, R., et al. 2002. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes. 51:1437-1442.
109. Shimabukuro, M., Wang, M.Y., Zhou, Y.T., Newgard, C.B., and Unger, R.H. 1998. Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc. Natl. Acad. Sci. U. S. A. 95:9558-9561.
110. Laedtke, T., et al. 2000. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 279:E520-E528.
111. Greenwood, R.H., Mahler, R.F., and Hales, C.N. 1976. Improvement in insulin secretion in diabetes after diazoxide. Lancet. 1:444-447.
112. Oyadomari, S., Araki, E., and Mori, M. 2002. Endoplasmic reticulum stress-mediated apoptosis in pancreatic beta-cells. Apoptosis. 7:335-345.
113. Izumi, T., et al. 2003. Dominant negative pathogenesis by mutant proinsulin in the Akita diabetic mouse. Diabetes. 52:409-416.
114. Moffitt, J.H., et al. 2005. Adverse physicochemical properties of tripalmitin in beta cells lead to morphological changes and lipotoxicity in vitro. Diabetologia. 48:1819-1829.
115. Turner, R.C., McCarthy, S.T., Holman, R.R., and Harris, E. 1976. Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. Br. Med. J. 1:1252-1254.
116. Rossetti, L., Shulman, G.I., Zawalich, W., and DeFronzo, R.A. 1987. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J. Clin. Invest. 80:1037-1044.
117. O'Brien, T.D., Butler, P.C., Westermark, P., and Johnson, K.H. 1993. Islet amyloid polypeptide: a review of its biology and potential roles in the pathogenesis of diabetes mellitus. Vet. Pathol. 30:317-332.
118. Laybutt, D.R., et al. 2003. Critical reduction in beta-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes. J. Biol. Chem. 278:2997-3005.
119. Kaneto, H., et al. 2001. Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress. J. Biol. Chem. 276:31099-31104.
120. Fu, M.X., et al. 1994. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 43:676-683.
121. Miyata, T., et al. 1994. Involvement of β 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis- associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin-1. J. Clin. Invest. 93:521-528.
122. Marzban, L., Park, K., and Verchere, C.B. 2003. Islet amyloid polypeptide and type 2 diabetes. Exp. Gerontol. 38:347-351.
123. Narita, R., et al. 1992. Islet amyloid polypeptide (IAPP) and pancreatic islet amyloid deposition in diabetic and non-diabetic patients. Diabetes Res. Clin. Pract. 15:3-14.
124. Butler, A.E., et al. 2004. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): a new model for type 2 diabetes. Diabetes. 53:1509-1516.
125. Buchanan, T.A., et al. 2002. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 51:2796-2803.